Sunday, 22 December 2024
  
Login

Australia's most trusted
source of pharma news

Sunday, 22 December 2024
News

CSL's big buy boosts pipeline

Posted 15 December 2021 AM

In its largest ever acquisition, CSL has announced it will buy Swiss pharma Vifor for US$12.3 billion (AU$17.2 billion) - a deal that adds 10 commercialised products to the Aussie biotech's swag and boosts the company's pipeline by a third.

The all-cash agreement approved by both boards of directors has been in the wind for some time, and values Vifor at US$179.25 per share, or US$11.7 billion. The US$12.3 billion buy price includes an assumed debt of 540 million Swiss francs (US$586 million).

To see the whole article, please login


Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.